
Bausch + Lomb Corporation
Bausch + Lomb Corporation is a Canada-based company in the Healthcare sector with a market capitalisation of $6.2B. Its FinScore is 50/100; its highest-scoring layer is Momentum (74) and its lowest is Growth (45).
Share price performance
About Bausch + Lomb Corporation
www.bausch.comBausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- HQ
- Canada
- Fiscal year-end
- December
- Trading currency
- USD
- Reporting currency
- USD
- Fundamentals updated
- 27 days ago
- Market cap
- $6.2B
- Shares outstanding
- 357.2M
- Beta (issuer)
- 0.56
- Revenue (latest FY)
- $5.1B
Revenue breakdown
- Device Products37.7%$1.9B
- Over the Counter Products36.0%$1.8B
- Pharmaceutical Products21.2%$1.1B
- Branded and Other Generic Products4.8%$243.0M
- Other Revenues0.4%$21.0M
FinScore
As of 2026-10-22Snapshot
Ownership
As of 2026-03-31Sign up or log in to see Analysis
Analysis for Bausch + Lomb Corporation is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Financials
Financials for Bausch + Lomb Corporation is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Estimates
Estimates for Bausch + Lomb Corporation is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Peers
Peers for Bausch + Lomb Corporation is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Valuation
Valuation for Bausch + Lomb Corporation is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see News
News for Bausch + Lomb Corporation is available to Finryse members. The Overview stays open to everyone; creating an account is free.